Ioflupane I-123

(DaTscan®)

DaTscan®

Latest News

loading GIF

Drug updated on 6/10/2024

Dosage FormInjection (intravenous; 74 MBq/mL [2 mCi/mL])
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with suspected Parkinsonian syndromes (PS)
  • Indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with suspected dementia with Lewy bodies (DLB)

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ioflupane I-123 (DaTscan) is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single-photon emission computed tomography (SPECT) brain imaging in adult patients with suspected Parkinsonian syndromes and dementia with Lewy bodies.
  • Three studies were examined, providing insights into the effectiveness and safety profiles of DaTscan compared to alternative diagnostic methods such as transcranial sonography (TCS).
  • The studies highlight that DaTscan shows high effectiveness in differentiating parkinsonian syndromes from other conditions like essential tremor or psychogenic tremor. It provides specific insights into dopamine transporter levels which can be pivotal for certain diagnoses.
  • Compared to TCS, while TCS offers similar diagnostic accuracy without radiation exposure, it has a high risk of bias in patient selection methodologies. However, being non-invasive and devoid of radiation makes TCS a viable initial screening tool where DaTscan accessibility might be limited due to cost or availability.
  • In terms of impact on management, approximately half the patients had their management plans altered post-DaTscan imaging; about one-third had their diagnoses changed after undergoing this scan. This underscores its value in therapeutic decision-making for suspected Parkinsonian syndrome cases.
  • There's a need for further research focusing on specific patient subgroups to understand better how effective DaTscan is across different demographics or disease stages.

Product Monograph / Prescribing Information

Document TitleYearSource
DaTscan (ioflupane I-123) Prescribing Information.2022GE Healthcare, Arlington Heights, IL

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
CANM guidelines for imaging of the dopamine transport system in evaluation of movement disorders. 2020The Canadian Journal of Nuclear Medicine
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0.2020European Journal of Nuclear Medicine and Molecular Imaging
Canadian guideline for Parkinson disease – Executive summary.2019Canadian Medical Association Journal
Canadian guideline for Parkinson disease.2019Canadian Medical Association Journal